Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

BUY
$26.75 - $46.02 $11.5 Million - $19.9 Million
431,547 Added 35.96%
1,631,547 $71.3 Million
Q4 2020

Feb 12, 2021

BUY
$15.96 - $50.0 $3.11 Million - $9.75 Million
194,954 Added 19.4%
1,200,000 $39.6 Million
Q3 2020

Nov 13, 2020

BUY
$16.77 - $20.65 $16.9 Million - $20.8 Million
1,005,046 New
1,005,046 $18.1 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $606M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Capital World Investors Portfolio

Follow Capital World Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.